Merck & Co., Inc. (NYSE: MRK) Stock Competitors & Peer Comparison
See MRK's competitors and their performance on the NYSE and across the wider stock market.
Peer Comparison Table: Drug Manufacturers - General Industry
Detailed financial metrics including price, market cap, P/E ratio, and more for MRK and its NYSE peers.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| MRK | $135.97 | +0.10% | 335.8B | 42.35 | $3.21 | +2.47% |
| LLY | $1,185.16 | +0.42% | 1.1T | 37.63 | $31.49 | +0.56% |
| JNJ | $262.37 | +0.78% | 632.4B | 24.46 | $10.73 | +2.00% |
| ABBV | $250.33 | +0.35% | 442.5B | 24.58 | $10.19 | +2.73% |
| NVS | $151.97 | +0.72% | 288.9B | 17.49 | $8.69 | +3.12% |
| AZN | $156.89 | +0.28% | 243.3B | 16.94 | $9.26 | +1.34% |
| AMGN | $419.38 | +1.00% | 226.3B | 18.75 | $22.37 | +2.35% |
| NVO | $44.88 | -2.20% | 199.3B | 11.17 | $4.02 | +2.60% |
| GILD | $138.92 | +0.40% | 172.5B | -356.21 | -$0.39 | +2.32% |
| PFE | $26.87 | +0.30% | 153.1B | 8.81 | $3.05 | +6.40% |
Stock Comparison
Eli Lilly and Company (NYSE: LLY)
MRK vs LLY Comparison August 2026
Merck & Co., Inc. (NYSE: MRK) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MRK stands at 335.8B. In comparison, LLY has a market cap of 1.1T. Regarding current trading prices, MRK is priced at $135.97 on the NYSE, while LLY trades at $1,185.16.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MRK currently has a P/E ratio of 42.35, whereas LLY's P/E ratio is 37.63. In terms of profitability, MRK's ROE is +0.07%, compared to LLY's ROE of +0.93%. Regarding short-term risk, MRK is less volatile compared to LLY. This indicates lower risk in terms of short-term price fluctuations for MRK.Check LLY's competition here
Johnson & Johnson (NYSE: JNJ)
MRK vs JNJ Comparison August 2026
Merck & Co., Inc. (NYSE: MRK) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MRK stands at 335.8B. In comparison, JNJ has a market cap of 632.4B. Regarding current trading prices, MRK is priced at $135.97 on the NYSE, while JNJ trades at $262.37.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MRK currently has a P/E ratio of 42.35, whereas JNJ's P/E ratio is 24.46. In terms of profitability, MRK's ROE is +0.07%, compared to JNJ's ROE of +0.26%. Regarding short-term risk, MRK is less volatile compared to JNJ. This indicates lower risk in terms of short-term price fluctuations for MRK.Check JNJ's competition here
AbbVie Inc. (NYSE: ABBV)
MRK vs ABBV Comparison August 2026
Merck & Co., Inc. (NYSE: MRK) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MRK stands at 335.8B. In comparison, ABBV has a market cap of 442.5B. Regarding current trading prices, MRK is priced at $135.97 on the NYSE, while ABBV trades at $250.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MRK currently has a P/E ratio of 42.35, whereas ABBV's P/E ratio is 24.58. In terms of profitability, MRK's ROE is +0.07%, compared to ABBV's ROE of -1.36%. Regarding short-term risk, MRK is more volatile compared to ABBV. This indicates higher risk in terms of short-term price fluctuations for MRK.Check ABBV's competition here
Novartis AG (NYSE: NVS)
MRK vs NVS Comparison August 2026
Merck & Co., Inc. (NYSE: MRK) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MRK stands at 335.8B. In comparison, NVS has a market cap of 288.9B. Regarding current trading prices, MRK is priced at $135.97 on the NYSE, while NVS trades at $151.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MRK currently has a P/E ratio of 42.35, whereas NVS's P/E ratio is 17.49. In terms of profitability, MRK's ROE is +0.07%, compared to NVS's ROE of +0.30%. Regarding short-term risk, MRK is more volatile compared to NVS. This indicates higher risk in terms of short-term price fluctuations for MRK.Check NVS's competition here
AstraZeneca PLC (NYSE: AZN)
MRK vs AZN Comparison August 2026
Merck & Co., Inc. (NYSE: MRK) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MRK stands at 335.8B. In comparison, AZN has a market cap of 243.3B. Regarding current trading prices, MRK is priced at $135.97 on the NYSE, while AZN trades at $156.89.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MRK currently has a P/E ratio of 42.35, whereas AZN's P/E ratio is 16.94. In terms of profitability, MRK's ROE is +0.07%, compared to AZN's ROE of +0.22%. Regarding short-term risk, MRK is more volatile compared to AZN. This indicates higher risk in terms of short-term price fluctuations for MRK.Check AZN's competition here
Amgen Inc. (NASDAQ: AMGN)
MRK vs AMGN Comparison August 2026
Merck & Co., Inc. (NYSE: MRK) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MRK stands at 335.8B. In comparison, AMGN has a market cap of 226.3B. Regarding current trading prices, MRK is priced at $135.97 on the NYSE, while AMGN trades at $419.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MRK currently has a P/E ratio of 42.35, whereas AMGN's P/E ratio is 18.75. In terms of profitability, MRK's ROE is +0.07%, compared to AMGN's ROE of +0.89%. Regarding short-term risk, MRK is less volatile compared to AMGN. This indicates lower risk in terms of short-term price fluctuations for MRK.Check AMGN's competition here
Novo Nordisk A/S (NYSE: NVO)
MRK vs NVO Comparison August 2026
Merck & Co., Inc. (NYSE: MRK) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MRK stands at 335.8B. In comparison, NVO has a market cap of 199.3B. Regarding current trading prices, MRK is priced at $135.97 on the NYSE, while NVO trades at $44.88.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MRK currently has a P/E ratio of 42.35, whereas NVO's P/E ratio is 11.17. In terms of profitability, MRK's ROE is +0.07%, compared to NVO's ROE of +0.59%. Regarding short-term risk, MRK is more volatile compared to NVO. This indicates higher risk in terms of short-term price fluctuations for MRK.Check NVO's competition here
Gilead Sciences, Inc. (NASDAQ: GILD)
MRK vs GILD Comparison August 2026
Merck & Co., Inc. (NYSE: MRK) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MRK stands at 335.8B. In comparison, GILD has a market cap of 172.5B. Regarding current trading prices, MRK is priced at $135.97 on the NYSE, while GILD trades at $138.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MRK currently has a P/E ratio of 42.35, whereas GILD's P/E ratio is -356.21. In terms of profitability, MRK's ROE is +0.07%, compared to GILD's ROE of -0.16%. Regarding short-term risk, MRK is less volatile compared to GILD. This indicates lower risk in terms of short-term price fluctuations for MRK.Check GILD's competition here
Pfizer Inc. (NYSE: PFE)
MRK vs PFE Comparison August 2026
Merck & Co., Inc. (NYSE: MRK) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MRK stands at 335.8B. In comparison, PFE has a market cap of 153.1B. Regarding current trading prices, MRK is priced at $135.97 on the NYSE, while PFE trades at $26.87.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MRK currently has a P/E ratio of 42.35, whereas PFE's P/E ratio is 8.81. In terms of profitability, MRK's ROE is +0.07%, compared to PFE's ROE of +0.05%. Regarding short-term risk, MRK is more volatile compared to PFE. This indicates higher risk in terms of short-term price fluctuations for MRK.Check PFE's competition here
Bristol-Myers Squibb Company (NYSE: BMY)
MRK vs BMY Comparison August 2026
Merck & Co., Inc. (NYSE: MRK) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MRK stands at 335.8B. In comparison, BMY has a market cap of 132.1B. Regarding current trading prices, MRK is priced at $135.97 on the NYSE, while BMY trades at $64.63.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MRK currently has a P/E ratio of 42.35, whereas BMY's P/E ratio is 10.90. In terms of profitability, MRK's ROE is +0.07%, compared to BMY's ROE of +0.47%. Regarding short-term risk, MRK is less volatile compared to BMY. This indicates lower risk in terms of short-term price fluctuations for MRK.Check BMY's competition here
Sanofi (NASDAQ: SNY)
MRK vs SNY Comparison August 2026
Merck & Co., Inc. (NYSE: MRK) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MRK stands at 335.8B. In comparison, SNY has a market cap of 106.6B. Regarding current trading prices, MRK is priced at $135.97 on the NYSE, while SNY trades at $44.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MRK currently has a P/E ratio of 42.35, whereas SNY's P/E ratio is 9.68. In terms of profitability, MRK's ROE is +0.07%, compared to SNY's ROE of +0.06%. Regarding short-term risk, MRK is more volatile compared to SNY. This indicates higher risk in terms of short-term price fluctuations for MRK.Check SNY's competition here
GSK plc (NYSE: GSK)
MRK vs GSK Comparison August 2026
Merck & Co., Inc. (NYSE: MRK) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MRK stands at 335.8B. In comparison, GSK has a market cap of 100.7B. Regarding current trading prices, MRK is priced at $135.97 on the NYSE, while GSK trades at $50.28.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MRK currently has a P/E ratio of 42.35, whereas GSK's P/E ratio is 10.86. In terms of profitability, MRK's ROE is +0.07%, compared to GSK's ROE of +0.24%. Regarding short-term risk, MRK is more volatile compared to GSK. This indicates higher risk in terms of short-term price fluctuations for MRK.Check GSK's competition here
Biogen Inc. (NASDAQ: BIIB)
MRK vs BIIB Comparison August 2026
Merck & Co., Inc. (NYSE: MRK) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MRK stands at 335.8B. In comparison, BIIB has a market cap of 30.9B. Regarding current trading prices, MRK is priced at $135.97 on the NYSE, while BIIB trades at $209.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MRK currently has a P/E ratio of 42.35, whereas BIIB's P/E ratio is 13.20. In terms of profitability, MRK's ROE is +0.07%, compared to BIIB's ROE of +0.05%. Regarding short-term risk, MRK is more volatile compared to BIIB. This indicates higher risk in terms of short-term price fluctuations for MRK.Check BIIB's competition here
Zoetis Inc. (NYSE: ZTS)
MRK vs ZTS Comparison August 2026
Merck & Co., Inc. (NYSE: MRK) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MRK stands at 335.8B. In comparison, ZTS has a market cap of 30.6B. Regarding current trading prices, MRK is priced at $135.97 on the NYSE, while ZTS trades at $72.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MRK currently has a P/E ratio of 42.35, whereas ZTS's P/E ratio is 11.09. In terms of profitability, MRK's ROE is +0.07%, compared to ZTS's ROE of +0.69%. Regarding short-term risk, MRK is less volatile compared to ZTS. This indicates lower risk in terms of short-term price fluctuations for MRK.Check ZTS's competition here
Horizon Therapeutics Public Limited Company (NASDAQ: HZNP)
MRK vs HZNP Comparison August 2026
Merck & Co., Inc. (NYSE: MRK) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MRK stands at 335.8B. In comparison, HZNP has a market cap of 26.6B. Regarding current trading prices, MRK is priced at $135.97 on the NYSE, while HZNP trades at $116.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MRK currently has a P/E ratio of 42.35, whereas HZNP's P/E ratio is 61.86. In terms of profitability, MRK's ROE is +0.07%, compared to HZNP's ROE of +0.11%. Regarding short-term risk, MRK is more volatile compared to HZNP. This indicates higher risk in terms of short-term price fluctuations for MRK.Check HZNP's competition here
Grifols, S.A. (NASDAQ: GRFS)
MRK vs GRFS Comparison August 2026
Merck & Co., Inc. (NYSE: MRK) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MRK stands at 335.8B. In comparison, GRFS has a market cap of 6.6B. Regarding current trading prices, MRK is priced at $135.97 on the NYSE, while GRFS trades at $7.77.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MRK currently has a P/E ratio of 42.35, whereas GRFS's P/E ratio is 8.92. In terms of profitability, MRK's ROE is +0.07%, compared to GRFS's ROE of +0.08%. Regarding short-term risk, MRK is more volatile compared to GRFS. This indicates higher risk in terms of short-term price fluctuations for MRK.Check GRFS's competition here
Organon & Co. (NYSE: OGN)
MRK vs OGN Comparison August 2026
Merck & Co., Inc. (NYSE: MRK) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MRK stands at 335.8B. In comparison, OGN has a market cap of 3.6B. Regarding current trading prices, MRK is priced at $135.97 on the NYSE, while OGN trades at $13.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MRK currently has a P/E ratio of 42.35, whereas OGN's P/E ratio is 4.09. In terms of profitability, MRK's ROE is +0.07%, compared to OGN's ROE of +0.23%. Regarding short-term risk, MRK is more volatile compared to OGN. This indicates higher risk in terms of short-term price fluctuations for MRK.Check OGN's competition here
Bristol-Myers Squibb Company Ce (NYSE: CELG-RI)
MRK vs CELG-RI Comparison August 2026
Merck & Co., Inc. (NYSE: MRK) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MRK stands at 335.8B. In comparison, CELG-RI has a market cap of 224.5M. Regarding current trading prices, MRK is priced at $135.97 on the NYSE, while CELG-RI trades at $0.11.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MRK currently has a P/E ratio of 42.35, whereas CELG-RI's P/E ratio is N/A. In terms of profitability, MRK's ROE is +0.07%, compared to CELG-RI's ROE of N/A. Regarding short-term risk, MRK is more volatile compared to CELG-RI. This indicates higher risk in terms of short-term price fluctuations for MRK.Check CELG-RI's competition here
Citius Oncology, Inc. (NASDAQ: CTOR)
MRK vs CTOR Comparison August 2026
Merck & Co., Inc. (NYSE: MRK) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MRK stands at 335.8B. In comparison, CTOR has a market cap of 71.4M. Regarding current trading prices, MRK is priced at $135.97 on the NYSE, while CTOR trades at $0.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MRK currently has a P/E ratio of 42.35, whereas CTOR's P/E ratio is -1.63. In terms of profitability, MRK's ROE is +0.07%, compared to CTOR's ROE of -1.03%. Regarding short-term risk, MRK is less volatile compared to CTOR. This indicates lower risk in terms of short-term price fluctuations for MRK.Check CTOR's competition here
Scilex Holding Company (NASDAQ: SCLX)
MRK vs SCLX Comparison August 2026
Merck & Co., Inc. (NYSE: MRK) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MRK stands at 335.8B. In comparison, SCLX has a market cap of 57.4M. Regarding current trading prices, MRK is priced at $135.97 on the NYSE, while SCLX trades at $6.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MRK currently has a P/E ratio of 42.35, whereas SCLX's P/E ratio is -0.17. In terms of profitability, MRK's ROE is +0.07%, compared to SCLX's ROE of +1.90%. Regarding short-term risk, MRK is less volatile compared to SCLX. This indicates lower risk in terms of short-term price fluctuations for MRK.Check SCLX's competition here
Scilex Holding Company (NASDAQ: SCLXW)
MRK vs SCLXW Comparison August 2026
Merck & Co., Inc. (NYSE: MRK) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MRK stands at 335.8B. In comparison, SCLXW has a market cap of 51.9M. Regarding current trading prices, MRK is priced at $135.97 on the NYSE, while SCLXW trades at $0.17.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MRK currently has a P/E ratio of 42.35, whereas SCLXW's P/E ratio is -0.01. In terms of profitability, MRK's ROE is +0.07%, compared to SCLXW's ROE of +1.90%. Regarding short-term risk, MRK is more volatile compared to SCLXW. This indicates higher risk in terms of short-term price fluctuations for MRK.Check SCLXW's competition here
MIRA Pharmaceuticals, Inc. (NASDAQ: MIRA)
MRK vs MIRA Comparison August 2026
Merck & Co., Inc. (NYSE: MRK) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MRK stands at 335.8B. In comparison, MIRA has a market cap of 33.2M. Regarding current trading prices, MRK is priced at $135.97 on the NYSE, while MIRA trades at $0.79.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MRK currently has a P/E ratio of 42.35, whereas MIRA's P/E ratio is -0.54. In terms of profitability, MRK's ROE is +0.07%, compared to MIRA's ROE of -1.07%. Regarding short-term risk, MRK is less volatile compared to MIRA. This indicates lower risk in terms of short-term price fluctuations for MRK.Check MIRA's competition here
BioDelivery Sciences Intl, Inc. Wrrt (NASDAQ: BDSIW)
MRK vs BDSIW Comparison August 2026
Merck & Co., Inc. (NYSE: MRK) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MRK stands at 335.8B. In comparison, BDSIW has a market cap of 0. Regarding current trading prices, MRK is priced at $135.97 on the NYSE, while BDSIW trades at $0.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MRK currently has a P/E ratio of 42.35, whereas BDSIW's P/E ratio is -0.43. In terms of profitability, MRK's ROE is +0.07%, compared to BDSIW's ROE of +0.57%. Regarding short-term risk, MRK is less volatile compared to BDSIW. This indicates lower risk in terms of short-term price fluctuations for MRK.Check BDSIW's competition here
Clarus Therapeutics Holdings, Inc. (NASDAQ: CRXT)
MRK vs CRXT Comparison August 2026
Merck & Co., Inc. (NYSE: MRK) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MRK stands at 335.8B. In comparison, CRXT has a market cap of 0. Regarding current trading prices, MRK is priced at $135.97 on the NYSE, while CRXT trades at $0.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MRK currently has a P/E ratio of 42.35, whereas CRXT's P/E ratio is -0.02. In terms of profitability, MRK's ROE is +0.07%, compared to CRXT's ROE of -4.63%. Regarding short-term risk, MRK is less volatile compared to CRXT. This indicates lower risk in terms of short-term price fluctuations for MRK.Check CRXT's competition here